病毒性肝炎患者的阿司匹林:观察性研究的系统审查和元分析
Wentao Bian1, Wenkai Bian2, Qingyu Li3
1Chengdu University of Traditional Chinese Medicine, Chengdu, China. bianwt3776@163.com.
Journal of gastrointestinal cancer
|April 1, 2024
概括
阿司匹林的使用显著降低慢性病毒性肝炎患者的肝癌风险. 然而,潜在的胃肠道出血风险需要仔细考虑和进一步研究.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 胃肠病学 胃肠病学
- 在瘤学瘤学.
背景情况:
- 肝细胞癌 (HCC) 是一个越来越严重的健康问题,特别是在慢性病毒性肝炎患者中.
- 虽然已知阿司匹林可以降低肝癌的发病率,但它对病毒性肝炎患者的具体益处仍然不确定.
研究的目的:
- 调查阿司匹林消费与患有慢性病毒性肝炎的患者患肝细胞癌 (HCC) 的风险之间的关联.
主要方法:
- 一个全面的系统文献综述和对2023年12月16日之前发表的研究进行元分析.
- 搜索的数据库包括PubMed,Embase,科学网和科克兰图书馆.
- 主要结局是HCC发病率;次要结局是胃肠道出血,使用危险比率 (HR) 和95%置信区间 (CI) 进行分析.
主要成果:
- 分析包括了13篇文章,超过30万名参与者.
- 阿司匹林使用与HCC发病率显著降低有关 (HR 0.75;95% CI,0.68-0.83).
- 观察到胃肠道出血的风险增加 (HR 1.13; 95% CI, 1.07-1.20),在HCV患者和长期使用者中可能有更大的益处.
结论:
- 阿司匹林使用与慢性病毒性肝炎患者肝癌风险显著降低有关.
- 胃肠道出血的可能性需要谨慎,并强调需要进一步验证这些发现.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
690
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
690
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
522
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
522
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K


